TY - JOUR T1 - Reassessing Th1 <em>versus</em> Th17.1 in sarcoidosis: new tricks for old dogma JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00010-2018 VL - 51 IS - 3 SP - 1800010 AU - Edward S. Chen Y1 - 2018/03/01 UR - http://erj.ersjournals.com/content/51/3/1800010.abstract N2 - Immunologically, sarcoidosis has been classically defined by the presence of a Th1-dominant environment localised to sites of disease, characterised by overexpression of interferon (IFN)γ and Th1-promoting interleukin (IL)12 and IL18 [1]. Accordingly, the downstream effects of enhanced Th1 are also observed in sarcoidosis, such as the expression of Th1-associated chemokines (MIG/CXCL9, IP10/CXCL10, ITAC/CXCL11, MCP1/CCL2, MIP1α/CCL3, MIP1β/CCL4, RANTES/CCL5) and their respective receptors (CXCR3, CCR5). Conversely, the presence of augmented Th2 has never been firmly documented in the sarcoidosis lung.While enhanced IFN-gamma expression remains a principal feature of sarcoidosis, its origin may involve factors beyond Th1 http://ow.ly/qtyB30i48bU ER -